Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amonerve
- Development stage
- Unknown
- Lead developer
- AS Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Amonerve** is an orally administered fixed-dose nutraceutical/pharmaceutical combination marketed by AS Pharmaceutical. A third-party product listing describes an Amonerve tablet containing alpha-lipoic acid, chromium picolinate, folic acid, methylcobalamin, myo-inositol, selenious acid, and zinc sulfate. AS Pharmaceutical lists Amonerve among its products, while a manufacturer directory associates the brand with chromium picolinate. Public sources reviewed do not establish a product-specific therapeutic indication or a single defined molecular target. ([sayacare.in](https://sayacare.in/brand/amonerve-tablet-69126))
- Brand names
- Amonerve
02
Targets
GPX4 (Glutathione peroxidase 4)INSR (Insulin receptor)MTR (Methionine synthase)MTHFR (Methylenetetrahydrofolate reductase)Misfolded SOD1
Beyond the preview
Go deeper on Amonerve.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amonerve.